

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **ImmuneOnco Biopharmaceuticals (Shanghai) Inc.**

### **宜明昂科生物醫藥技術（上海）股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 1541)**

## **DATE OF BOARD MEETING**

The board (the “**Board**”) of directors (the “**Directors**”) of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the “**Company**”) hereby announces that a meeting of the Board will be held on Tuesday, 25 March 2025 for the purpose of, among other matters, considering and approving the annual results of the Company and its subsidiaries for the year ended 31 December 2024 and its publication and considering the recommendation on the payment of a final dividend, if any.

By order of the Board

**ImmuneOnco Biopharmaceuticals (Shanghai) Inc.**

**宜明昂科生物醫藥技術（上海）股份有限公司**

**Tian Wenzhi**

*Chairman and Executive Director*

Shanghai, the PRC, 13 March 2025

*As at the date of this announcement, the Board of Directors comprises (i) Dr. Tian Wenzhi, Mr. Li Song and Ms. Guan Mei as executive Directors; (ii) Dr. Xu Cong as non-executive Director; and (iii) Dr. Zhenping Zhu, Dr. Kendall Arthur Smith and Mr. Yeung Chi Tat as independent non-executive Directors.*